Remibrutinib achieves complete response for the three most common subtypes of chronic inducible urticaria in a phase 3 clinical trial.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/remibrutinib-resolves-symptoms-most-common-chronic-inducible-2026a1000kgo?src=rss
Author :
Publish date : 2026-06-17 12:36:00
Copyright for syndicated content belongs to the linked Source.
